Adaptix Interbody System features a proprietary blend of surface textures on the macro, micro, and nano levels. Credit: Medtronic plc.

Medtronic has launched its Adaptix Interbody System, which received US Food and Drug Administration (FDA) approval in August, in the US.

Interbody implants are spacers placed between the vertebrae during spinal fusion surgery to minimise the pressure on nerves and to keep the vertebrae in place during the fusion.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Considered to be the first navigated titanium implant with Titan nanoLOCK Surface Technology, Adaptix Interbody System has a proprietary blend of surface textures on the macro, micro, and nano levels.

The Adaptix Interbody System is similar to the Capstone Spinal System. It includes enhanced features for increased strength, subsidence resistance, easy insertion, and data-backed bone growth.

Titan nanoLOCK Surface Technology was developed by Titan Spine, which was acquired by Medtronic last year.

It is the first technology to demonstrate the elements to be considered nanotechnology for spinal devices as suggested in the FDA nanotechnology guidance document.

Medtronic Restorative Therapies Group Core Spine and Biologics division vice-president and general manager Sharrolyn Josse said: “Adaptix Interbody System is an exciting addition to our portfolio that leads with our Titan nanoLOCK Surface Technology. It is a fully navigated procedure, leveraging our leadership in navigation.”

Adaptix Interbody System is compatible with the Medtronic’s StealthStation Navigation and O-arm imaging platform and Grafton DBF Inject, a graft delivery syringe designed to release an osteoinductive DBM into the surgical site.

Last month, Medtronic announced the acquisition of Avenu Medical, a privately held medical device company focused on the endovascular creation of arteriovenous (AV) fistulae for patients with end-stage renal disease (ESRD), undergoing dialysis.